GALT - GALECTIN THERAPEUTICS INC

1.325
0.005   0.377%

Share volume: 296,924
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$1.32
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
26%
Profitability 0%
Dept financing 50%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.52%
1 Month
-16.67%
3 Months
17.26%
6 Months
-51.64%
1 Year
-64.57%
2 Year
-34.41%
Key data
Stock price
$1.32
P/E Ratio 
0.00
DAY RANGE
$1.23 - $1.48
EPS 
-$0.68
52 WEEK RANGE
$0.73 - $4.27
52 WEEK CHANGE
-$66.37
MARKET CAP 
171.265 M
YIELD 
N/A
SHARES OUTSTANDING 
62.278 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
2.48
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$284,460
AVERAGE 30 VOLUME 
$288,411
Company detail
CEO: Joel Lewis
Region: US
Website: galectintherapeutics.com
Employees: 9
IPO year: 2002
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Galectin Therapeutics Inc. engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer. Belapectins is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis.

Recent news
loading